198 related articles for article (PubMed ID: 36032657)
21. Use of an expanded immunohistochemical panel to distinguish cutaneous Hodgkin lymphoma from histopathologic imitators.
Cho RJ; McCalmont TH; Ai WZ; Fox LP; Treseler P; Pincus LB
J Cutan Pathol; 2012 Jun; 39(6):651-8. PubMed ID: 22324490
[TBL] [Abstract][Full Text] [Related]
22. 9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial.
Gerhard-Hartmann E; Goergen H; Bröckelmann PJ; Mottok A; Steinmüller T; Grund J; Zamò A; Ben-Neriah S; Sasse S; Borchmann S; Fuchs M; Borchmann P; Reinke S; Engert A; Veldman J; Diepstra A; Klapper W; Rosenwald A
Br J Haematol; 2022 Jan; 196(1):116-126. PubMed ID: 34520052
[TBL] [Abstract][Full Text] [Related]
23. Biologic features of Hodgkin lymphoma and the development of biologic prognostic factors in Hodgkin lymphoma: tumor and microenvironment.
Hsi ED
Leuk Lymphoma; 2008 Sep; 49(9):1668-80. PubMed ID: 18798102
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical expression of vitamin D receptor and forkhead box P3 in classic Hodgkin lymphoma: correlation with clinical and pathologic findings.
Gupta GK; Agrawal T; Pilichowska M
BMC Cancer; 2020 Jun; 20(1):535. PubMed ID: 32513132
[TBL] [Abstract][Full Text] [Related]
25. The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study.
Agostinelli C; Gallamini A; Stracqualursi L; Agati P; Tripodo C; Fuligni F; Sista MT; Fanti S; Biggi A; Vitolo U; Rigacci L; Merli F; Patti C; Romano A; Levis A; Trentin L; Stelitano C; Borra A; Piccaluga PP; Hamilton-Dutoit S; Kamper P; Zaucha JM; Małkowski B; Kulikowski W; Tajer J; Subocz E; Rybka J; Steidl C; Broccoli A; Argnani L; Gascoyne RD; d'Amore F; Zinzani PL; Pileri SA
Lancet Haematol; 2016 Oct; 3(10):e467-e479. PubMed ID: 27692305
[TBL] [Abstract][Full Text] [Related]
26. AP1-dependent galectin-1 expression delineates classical hodgkin and anaplastic large cell lymphomas from other lymphoid malignancies with shared molecular features.
Rodig SJ; Ouyang J; Juszczynski P; Currie T; Law K; Neuberg DS; Rabinovich GA; Shipp MA; Kutok JL
Clin Cancer Res; 2008 Jun; 14(11):3338-44. PubMed ID: 18519761
[TBL] [Abstract][Full Text] [Related]
27. Detection of genomic imbalances in microdissected Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma by array-based comparative genomic hybridization.
Hartmann S; Martin-Subero JI; Gesk S; Hüsken J; Giefing M; Nagel I; Riemke J; Chott A; Klapper W; Parrens M; Merlio JP; Küppers R; Bräuninger A; Siebert R; Hansmann ML
Haematologica; 2008 Sep; 93(9):1318-26. PubMed ID: 18641027
[TBL] [Abstract][Full Text] [Related]
28. 3D connectomes of reactive and neoplastic CD30 positive lymphoid cells and surrounding cell types.
Lumer L; Wurzel P; Scharf S; Schäfer H; Ackermann J; Koch I; Hansmann ML
Acta Histochem; 2021 Jul; 123(5):151750. PubMed ID: 34233254
[TBL] [Abstract][Full Text] [Related]
29. Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma.
Roemer MGM; Redd RA; Cader FZ; Pak CJ; Abdelrahman S; Ouyang J; Sasse S; Younes A; Fanale M; Santoro A; Zinzani PL; Timmerman J; Collins GP; Ramchandren R; Cohen JB; De Boer JP; Kuruvilla J; Savage KJ; Trneny M; Ansell S; Kato K; Farsaci B; Sumbul A; Armand P; Neuberg DS; Pinkus GS; Ligon AH; Rodig SJ; Shipp MA
J Clin Oncol; 2018 Apr; 36(10):942-950. PubMed ID: 29394125
[TBL] [Abstract][Full Text] [Related]
30. Pathway-focused gene expression profiles and immunohistochemistry detection identify contrasting association of caspase 3 (CASP3) expression with prognosis in pediatric classical Hodgkin lymphoma.
Vera-Lozada G; Segges P; Stefanoff CG; Barros MHM; Niedobitek G; Hassan R
Hematol Oncol; 2018 Oct; 36(4):663-670. PubMed ID: 29901224
[TBL] [Abstract][Full Text] [Related]
31. Revisiting IL-6 expression in the tumor microenvironment of classical Hodgkin lymphoma.
Gholiha AR; Hollander P; Glimelius I; Hedstrom G; Molin D; Hjalgrim H; Smedby KE; Hashemi J; Amini RM; Enblad G
Blood Adv; 2021 Mar; 5(6):1671-1681. PubMed ID: 33720338
[TBL] [Abstract][Full Text] [Related]
32. IMP3 as a supplemental diagnostic marker for Hodgkin lymphoma.
Tang H; Wei Q; Ge J; Jian W; Liu J; Zhong L; Fu B; Zhao T
Hum Pathol; 2013 Oct; 44(10):2167-72. PubMed ID: 23845468
[TBL] [Abstract][Full Text] [Related]
33. Matrix metalloproteinase-9 expression by Hodgkin-Reed-Sternberg cells is associated with reduced overall survival in young adult patients with classical Hodgkin lymphoma.
Campos AH; Vassallo J; Soares FA
PLoS One; 2013; 8(9):e74793. PubMed ID: 24086377
[TBL] [Abstract][Full Text] [Related]
34. Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma.
Jones K; Vari F; Keane C; Crooks P; Nourse JP; Seymour LA; Gottlieb D; Ritchie D; Gill D; Gandhi MK
Clin Cancer Res; 2013 Feb; 19(3):731-42. PubMed ID: 23224400
[TBL] [Abstract][Full Text] [Related]
35. Primary cutaneous follicle center lymphoma with Hodgkin and Reed-Sternberg-like cells: a new histopathologic variant.
Dilly M; Ben-Rejeb H; Vergier B; Feldis M; Toty L; Nohra O; Beylot-Barry M; Gros A; Merlio JP; Parrens M
J Cutan Pathol; 2014 Oct; 41(10):797-801. PubMed ID: 25099172
[TBL] [Abstract][Full Text] [Related]
36. Whole-slide image analysis identifies a high content of Hodgkin Reed-Sternberg cells and a low content of T lymphocytes in tumor microenvironment as predictors of adverse outcome in patients with classic Hodgkin lymphoma treated with ABVD.
Santisteban-Espejo A; Bernal-Florindo I; Perez-Requena J; Atienza-Cuevas L; Maira-Gonzalez N; Garcia-Rojo M
Front Oncol; 2022; 12():1000762. PubMed ID: 36338756
[TBL] [Abstract][Full Text] [Related]
37. [Microenvironment in classical Hodgkin lymphoma].
Mottok A
Pathologe; 2020 May; 41(3):254-260. PubMed ID: 32239325
[TBL] [Abstract][Full Text] [Related]
38. New molecular targets in Hodgkin and Reed-Sternberg cells.
Sadaf H; Ambroziak M; Binkowski R; Kluebsoongnoen J; Paszkiewicz-Kozik E; Steciuk J; Markowicz S; Walewski J; Sarnowska E; Sarnowski TJ; Konopinski R
Front Immunol; 2023; 14():1155468. PubMed ID: 37266436
[TBL] [Abstract][Full Text] [Related]
39. Mass cytometry of Hodgkin lymphoma reveals a CD4
Cader FZ; Schackmann RCJ; Hu X; Wienand K; Redd R; Chapuy B; Ouyang J; Paul N; Gjini E; Lipschitz M; Armand P; Wu D; Fromm JR; Neuberg D; Liu XS; Rodig SJ; Shipp MA
Blood; 2018 Aug; 132(8):825-836. PubMed ID: 29880615
[TBL] [Abstract][Full Text] [Related]
40. 9p24.1 Genetic Alteration and PD-L1 Expression Are Characteristic of De Novo and Methotrexate-associated Epstein-Barr Virus-positive Hodgkin Lymphoma, But Not Methotrexate-associated Hodgkin-like Lesions.
Shiraiwa S; Kikuti YY; Carreras J; Kondo Y; Ohmachi K; Ogawa Y; Kawada H; Sato S; Gion Y; Sato Y; Nakamura N; Ando K
Am J Surg Pathol; 2022 Aug; 46(8):1017-1024. PubMed ID: 35848760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
